Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded to “Strong-Buy” at Wall Street Zen

Wall Street Zen upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a buy rating to a strong-buy rating in a research report sent to investors on Saturday morning.

Other equities analysts have also issued reports about the company. The Goldman Sachs Group boosted their price target on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Jefferies Financial Group lifted their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Scotiabank initiated coverage on Teva Pharmaceutical Industries in a research report on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 target price for the company. Finally, Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Three research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $33.67.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $32.03 on Friday. The company’s fifty day moving average is $28.04 and its two-hundred day moving average is $21.56. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $32.91. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82. The firm has a market capitalization of $36.73 billion, a price-to-earnings ratio of 53.38, a P/E/G ratio of 1.86 and a beta of 0.66.

Insider Activity

In other news, VP Richard Daniell sold 115,468 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the transaction, the vice president owned 48,384 shares in the company, valued at approximately $1,387,653.12. The trade was a 70.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Mark Sabag sold 216,892 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total value of $6,231,307.16. Following the completion of the transaction, the insider directly owned 52,828 shares in the company, valued at $1,517,748.44. The trade was a 80.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 622,060 shares of company stock valued at $17,076,965. Company insiders own 0.49% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Hedge funds and other institutional investors have recently bought and sold shares of the business. Grove Bank & Trust boosted its stake in Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after purchasing an additional 750 shares in the last quarter. Cromwell Holdings LLC raised its holdings in shares of Teva Pharmaceutical Industries by 40.3% in the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after buying an additional 629 shares during the last quarter. Advisors Asset Management Inc. acquired a new position in Teva Pharmaceutical Industries during the 2nd quarter worth about $41,000. Rothschild Investment LLC lifted its position in Teva Pharmaceutical Industries by 97.0% during the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock worth $55,000 after buying an additional 1,348 shares in the last quarter. Finally, JFS Wealth Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 257.1% during the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock worth $56,000 after acquiring an additional 2,000 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.